Matthew Lang's Net Worth
$3.34 Million
Who is Matthew Lang?
Matthew Lang has an estimated net worth of $3.34 Million. This is based on reported shares across multiple companies, which include Myovant Sciences Ltd., and Lyell Immunopharma, Inc..
SEC CIK
Matthew Lang's CIK is 0001712069
Past Insider Trading and Trends
2020 was Matthew Lang's most active year for acquiring shares with 9 total transactions. Matthew Lang's most active month to acquire stocks was the month of July. 2020 was Matthew Lang's most active year for disposing of shares, totalling 15 transactions. Matthew Lang's most active month to dispose stocks was the month of July. 2021 saw Matthew Lang paying a total of $233,400.00 for 178,771 shares, this is the most they've acquired in one year. In 2021 Matthew Lang cashed out on 84,487 shares for a total of $1,248,140.54, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Myovant Sciences Ltd. No price found
General Counsel & Corp. Secy.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -354.30K |
—
|
—
|
0
|
Mar 10
| |||
Form 4
| -0.36% | -1.27K |
$26.89 | -$34,204.08 | 354.3K |
Jan 18
| |||
Form 4
| -0.78% | -2.78K |
$26.90 | -$74,755.10 | 355.57K |
Jan 4
| |||
Form 4
| -0.54% | -1.93K |
$25.20 | -$48,711.60 | 358.35K |
Oct 18
| |||
Form 4
| -1.01% | -3.68K |
$24.40 | -$89,767.60 | 360.29K |
Oct 4
| |||
Form 4
| +34.60% | 93.57K |
$18.23 | -$569,031.22 | 363.97K |
Aug 12 - Aug 15
| |||
Form 4
| -0.71% | -1.94K |
$12.87 | -$24,903.45 | 270.4K |
Jul 18
| |||
Form 4
| -1.34% | -3.70K |
$13.40 | -$49,606.80 | 272.33K |
Jul 6
| |||
Form 4
| -2.82% | -8.00K |
$10.45 | -$83,620.90 | 276.04K |
Apr 19
| |||
Form 4
| +64.25% | 111.11K |
—
|
—
| 284.04K |
Apr 15
| |||
Form 4
| -1.39% | -2.44K |
$13.78 | -$33,568.08 | 172.93K |
Apr 5
| |||
Form 4
| -2.49% | -4.47K |
$16.27 | -$72,808.25 | 175.36K |
Jan 4
| |||
Form 4
| -3.58% | -6.67K |
$21.62 | -$144,227.02 | 179.84K |
Oct 5
| |||
Form 4
| -3.59% | -6.95K |
$21.52 | -$149,650.08 | 186.51K |
Jul 9
| |||
Form 4
| +43.30% | 58.46K |
—
|
—
| 193.46K |
Apr 15
| |||
Form 4
| -7.45% | -10.86K |
$18.62 | -$202,250.44 | 135K |
Apr 6
| |||
Form 4
|
—
|
0
|
$16.43 | -$518,613.00 | 145.87K |
Scheduled
|
Mar 15
| ||
Form 4
|
—
|
0
|
$16.60 | -$176,254.10 | 145.87K |
Scheduled
|
Dec 18
| ||
Form 4
|
—
|
0
|
$16.49 | -$348,232.02 | 145.87K |
Scheduled
|
Dec 9 - Dec 10
| ||
Form 4
|
—
|
0
|
$13.92 | -$327,555.60 | 145.87K |
Scheduled
|
Aug 31
| ||
Form 4
|
—
|
0
|
$13.90 | -$33,046.00 | 145.87K |
Scheduled
|
Aug 26 - Aug 28
| ||
Form 4
|
—
|
0
|
$13.89 | -$7,332.00 | 145.87K |
Scheduled
|
Aug 19
| ||
Form 4
| +321.61% | 111.27K |
—
|
—
| 145.87K |
Apr 3
| |||
Form 4
| -35.47% | -19.02K |
$15.55 | -$295,729.90 | 34.6K |
Dec 30
| |||
Form 4
|
∞
| 53.62K |
—
|
—
| 53.62K |
Aug 26
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Lyell Immunopharma, Inc. (LYEL) Snapshot price: $1.2
Chief Business Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 50K |
—
|
—
| 50K |
Feb 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||